Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma Journal Article

  


Authors: Samples, L.; Sadrzadeh, H.; Frigault, M. J.; Jacobson, C. A.; Hamadani, M.; Gurumurthi, A.; Strati, P.; Shouval, R.; Noy, A.; Riedell, P. A.; Dahiya, S.; Maloney, D. G.; Till, B. G.; Hirayama, A. V.; Gauthier, J.; Gopal, A. K.; Smith, S. D.; Poh, C.; Lynch, R.; Ujjani, C.; Di, M.; Raghunathan, V.; Shakib-Azar, M.; Naresh, K. N.; Gooley, T. A.; Yared, J.; Jain, M. D.; Locke, F. L.; Leslie, L. A.; Epperla, N.; Ghosh, M.; Skarbnik, A.; Hill, B. T.; Kamdar, M. K.; Ortiz-Maldonado, V.; Martinez-Cibrian, N.; Shune, L.; Shadman, M.
Article Title: Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Abstract: Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients. © 2025 American Society of Hematology
Keywords: adult; clinical article; aged; unclassified drug; human cell; overall survival; allogeneic stem cell transplantation; gemcitabine; cytarabine; methotrexate; rituximab; neurotoxicity; progression free survival; cohort analysis; relapse; steroid; medical record review; retrospective study; confidence interval; multicenter study; chimeric antigen receptor; oxaliplatin; burkitt lymphoma; recipient; clinical outcome; cytokine release syndrome; overall response rate; mortality rate; human; male; female; article; tisagenlecleucel t; chimeric antigen receptor t-cell immunotherapy; axicabtagene ciloleucel; lisocabtagene maraleucel; immune effector cell associated neurotoxicity; cd19 chimeric antigen receptor; varnimcabtagene autoleucel
Journal Title: Blood
Volume: 145
Issue: 23
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2025-01-01
Start Page: 2762
End Page: 2767
Language: English
DOI: 10.1182/blood.2024026831
PUBMED: 39938007
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-105001231815&doi=10.1182%2fblood.2024026831&partnerID=40&md5=fa904e925aac9e775bd994802819316a
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
Related MSK Work